Access Scientific announces that its POWERWAND™ midline now has over 20,000 catheter days of published scientific data without a single catheter-related bloodstream infection (CRBSI). This follows publication of a groundbreaking POWERWAND study-which has captured the attention of the infection prevention community--in the March 2017 issue of Journal of the Association for Vascular Access (JAVA).
Evidence of the POWERWAND’s consistently superior performance has now been demonstrated across five peer-reviewed, published studies and seven scientific posters. Results from the accumulated evidence base of 20,000 catheter-days shows the POWERWAND to have zero bloodstream infections (BSIs), superior blood drawability, and the lowest total complication rate and highest completion-of-therapy rate of any vascular access device on the market.
The most recent study in JAVA is titled "Vancomycin Administration Through a Novel Midline Catheter: Summary of a 5-Year, 1086-Patient Experience in an Urban Community Hospital." It examined more than 8,000 catheter-days using the POWERWAND for the long and short-term administration of vancomycin. In addition to zero reported bloodstream infections, there were also no reported cases of deep vein thrombosis or extravasation. The total complication rate of only 2.7 percent is far lower than any other vascular access device.
POWERWAND is made of a unique catheter material (ChronoFlex C®) that, when coupled with Access Scientific’s proprietary manufacturing processes, produces a catheter capable of outperforming the competition.
“The compendium of evidence attesting to POWERWAND’s superior performance is remarkable,” said Jeff Goble, CEO of Access Scientific. “POWERWAND’s proprietary material and manufacturing process has no equal among other catheters. POWERWAND is truly the evidence-based, best-in-class catheter of its kind.”
Source: Access Scientific, LLC